Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| macrophage | 21 studies | 26% ± 7% | |
| classical monocyte | 17 studies | 31% ± 10% | |
| monocyte | 10 studies | 28% ± 9% | |
| myeloid cell | 10 studies | 31% ± 10% | |
| microglial cell | 8 studies | 29% ± 9% | |
| conventional dendritic cell | 5 studies | 27% ± 10% | |
| dendritic cell | 5 studies | 22% ± 5% | |
| neutrophil | 4 studies | 25% ± 10% | |
| alveolar macrophage | 4 studies | 23% ± 8% | |
| mast cell | 3 studies | 43% ± 12% |
Insufficient scRNA-seq data for expression of PTAFR at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 99% | 1777.81 | 575 / 578 | 96% | 26.13 | 1108 / 1155 |
| esophagus | 95% | 639.06 | 1371 / 1445 | 96% | 18.75 | 176 / 183 |
| breast | 90% | 482.05 | 411 / 459 | 93% | 16.34 | 1035 / 1118 |
| intestine | 94% | 569.12 | 912 / 966 | 79% | 13.15 | 418 / 527 |
| bladder | 90% | 432.00 | 19 / 21 | 83% | 15.88 | 419 / 504 |
| kidney | 87% | 509.26 | 77 / 89 | 85% | 17.46 | 765 / 901 |
| stomach | 84% | 333.44 | 300 / 359 | 84% | 17.18 | 239 / 286 |
| thymus | 74% | 243.21 | 483 / 653 | 78% | 10.65 | 474 / 605 |
| pancreas | 53% | 161.49 | 173 / 328 | 93% | 26.90 | 166 / 178 |
| uterus | 55% | 157.30 | 94 / 170 | 87% | 22.45 | 398 / 459 |
| skin | 69% | 327.25 | 1240 / 1809 | 72% | 12.83 | 342 / 472 |
| brain | 50% | 199.61 | 1308 / 2642 | 89% | 20.16 | 630 / 705 |
| prostate | 83% | 293.96 | 204 / 245 | 45% | 3.16 | 224 / 502 |
| ovary | 29% | 74.15 | 53 / 180 | 88% | 15.71 | 379 / 430 |
| adrenal gland | 89% | 407.68 | 230 / 258 | 22% | 1.75 | 50 / 230 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 63.25 | 29 / 29 |
| peripheral blood | 100% | 10930.89 | 929 / 929 | 0% | 0 | 0 / 0 |
| spleen | 100% | 2643.09 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 98% | 33.73 | 44 / 45 |
| adipose | 97% | 813.97 | 1163 / 1204 | 0% | 0 | 0 / 0 |
| liver | 31% | 97.05 | 69 / 226 | 36% | 5.08 | 147 / 406 |
| blood vessel | 58% | 296.01 | 775 / 1335 | 0% | 0 | 0 / 0 |
| heart | 43% | 121.15 | 368 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 19% | 1.31 | 15 / 80 |
| muscle | 5% | 9.32 | 38 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0031663 | Biological process | lipopolysaccharide-mediated signaling pathway |
| GO_1904306 | Biological process | positive regulation of gastro-intestinal system smooth muscle contraction |
| GO_0032959 | Biological process | inositol trisphosphate biosynthetic process |
| GO_0006954 | Biological process | inflammatory response |
| GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0048661 | Biological process | positive regulation of smooth muscle cell proliferation |
| GO_0006935 | Biological process | chemotaxis |
| GO_0060732 | Biological process | positive regulation of inositol phosphate biosynthetic process |
| GO_0071258 | Biological process | cellular response to gravity |
| GO_0043315 | Biological process | positive regulation of neutrophil degranulation |
| GO_0002693 | Biological process | positive regulation of cellular extravasation |
| GO_1903238 | Biological process | positive regulation of leukocyte tethering or rolling |
| GO_0009609 | Biological process | response to symbiotic bacterium |
| GO_0006955 | Biological process | immune response |
| GO_0071548 | Biological process | response to dexamethasone |
| GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
| GO_0071320 | Biological process | cellular response to cAMP |
| GO_0045776 | Biological process | negative regulation of blood pressure |
| GO_0035589 | Biological process | G protein-coupled purinergic nucleotide receptor signaling pathway |
| GO_1904317 | Biological process | cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine |
| GO_1904300 | Biological process | positive regulation of transcytosis |
| GO_0045727 | Biological process | positive regulation of translation |
| GO_0045056 | Biological process | transcytosis |
| GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
| GO_1904303 | Biological process | positive regulation of maternal process involved in parturition |
| GO_0007567 | Biological process | parturition |
| GO_0032755 | Biological process | positive regulation of interleukin-6 production |
| GO_0071398 | Biological process | cellular response to fatty acid |
| GO_0030667 | Cellular component | secretory granule membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0016020 | Cellular component | membrane |
| GO_0070821 | Cellular component | tertiary granule membrane |
| GO_0004930 | Molecular function | G protein-coupled receptor activity |
| GO_0004992 | Molecular function | platelet activating factor receptor activity |
| GO_0005543 | Molecular function | phospholipid binding |
| GO_0051019 | Molecular function | mitogen-activated protein kinase binding |
| GO_0001875 | Molecular function | lipopolysaccharide immune receptor activity |
| GO_0045028 | Molecular function | G protein-coupled purinergic nucleotide receptor activity |
| GO_0001530 | Molecular function | lipopolysaccharide binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | PTAFR |
| Protein name | Platelet-activating factor receptor (PAF-R) (PAFr) |
| Synonyms | PAFR |
| Description | FUNCTION: Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth-muscle contractile and hypotensive activity. Seems to mediate its action via a G protein that activates a phosphatidylinositol-calcium second messenger system. . |
| Accessions | ENST00000539896.1 ENST00000373857.8 ENST00000305392.3 P25105 |
